Fig. 1From: Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trialIncidence rates of outcomes in the placebo group in those with versus those without metabolic syndrome at baseline. *Excluding fatal stroke. CV cardiovascular, HHF hospitalization for HF, PY patient yearsBack to article page